There are several reported cases of various neurological adverse effects following the COVID-19 vaccination globally. Acute vaccine-related encephalopathy and acute disseminated encephalomyelitis (ADEM) are included among them. Here we are reporting three cases of ADEM and one case of acute vaccine-related encephalopathy from Bangladesh, which have a possible association with COVID-19 vaccines. All three ADEM cases were elderly; two cases developed symptoms after receiving the second dose of the Sinopharm vaccine, and another case after receiving the second dose of the Sinovac vaccine. We have treated another case of acute vaccine-related encephalopathy following receiving the Moderna vaccine. The patients had features of encephalopathy, including altered consciousness and convulsions. The ADEM cases had MRI (magnetic resonance imaging) brain findings suggestive of ADEM. The other case had normal MRI findings. All the cases were treated with intravenous corticosteroids with full recovery, except for one ADEM patient, who developed aspiration pneumonia and died. Though it is not possible to conclude that COVID-19 vaccination is the causative agent behind these cases, this case series will help to increase awareness regarding the early detection and treatment of these serious adverse effects.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310056 | PMC |
| http://dx.doi.org/10.7759/cureus.39724 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial.
Vaccine
January 2025
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA; Department of Medicine, University of California, San Diego, (UCSD), La Jolla, CA, 92037, USA. Electronic address:
Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and lower-middle-income countries is needed. NDV-HXP-S is an inactivated egg-based recombinant Newcastle disease virus vaccine expressing the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A public sector manufacturer in Vietnam assessed the immunogenicity of NDV-HXP-S (COVIVAC) relative to an authorized vaccine.
View Article and Find Full Text PDFCOVID-19 and PIMS-TS-related admissions to paediatric intensive care in the Republic of Ireland January 2020 and July 2022 and analysis of cardiovascular manifestations of their disease.
Cardiol Young
November 2024
Paediatric Intensive Care Department and Children's heart centre, Children's Health Ireland at Crumlin, Dublin, Republic of Ireland.
Article Synopsis
- Researchers studied children in Ireland admitted to pediatric ICU for COVID-19 or related conditions between January 2020 and August 2022 to understand illness severity and outcomes.
- Out of 127 children, the majority had acute COVID-19 (68.5%) or Pediatric Inflammatory Multisystem Syndrome (30.7%), with those in the PIMS-TS group requiring more intensive cardiac support.
- Despite the high incidence of cardiac issues during hospitalization, all patients survived and showed normal heart function upon discharge.
Evaluation of Immunoglobulin A Enzyme Immunoassays to Detect Primary Respiratory Syncytial Virus Infection in Infants and Young Children.
J Infect Dis
November 2024
Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine.
Background: Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections in children <2 years of age. Prior infection in a child is usually determined by RSV antibodies; however, in young children, persisting maternal immunoglobulin G antibodies can incorrectly indicate past RSV infection. We developed and evaluated 4 immunoglobulin A (IgA) antibody enzyme immunoassays (EIAs) with the RSV F, subgroup G (Ga or Gb proteins) or RSV lysate antigens to distinguish infection induced from persisting maternal RSV antibodies.
View Article and Find Full Text PDFNon-COVID Admissions to the ICU After COVID Vaccination: A Multicenter Study.
Cureus
October 2024
Biostatistics, St John's Research Institute, Bengaluru, IND.
Introduction: The vaccination drive for COVID-19 was launched in India after the authorization of ChAdOx1 nCov-19 (Covishield), an adenoviral vector vaccine, and BBV152 COVID-19 (Covaxin), an inactivated virus vaccine. As stated by the CDC, vaccine-related adverse events can happen. In this study, we aimed to assess the timing of the COVID vaccination and admission diagnosis and their effect on ICU mortality.
View Article and Find Full Text PDFThe role of leukocyte activation in suspected Non-IgE excipient-related COVID-19 vaccine reactions: An exploratory hypothesis-driven study of pathogenesis.
Allergy Asthma Proc
November 2024
Department of Pediatrics, Georgetown University School of Medicine, Washington, D.C.
Adverse allergic reactions due to the administration of vaccines developed for the protection of coronavirus disease 2019 (COVID-19) have been reported since the initiation of the vaccination campaigns in December 15, 2020. Current analyses provided by the Centers for Disease Control and Prevention and the U.S.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!